Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages 1-9

  Kramer, Caroline K ^a,b   Zinman, Bernard ^a,b,c   Choi, Haysook ^a   Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE INTERVAL; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SECRETION SENSITIVITY INDEX 2; INSULIN SENSITIVITY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE;

EID: 85006228086     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2016-000270     Document Type: Article

References (29)

1. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28-34.
2. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on betacell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60.
3. Chen HS, Wu TE, Jap TS, et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-32.
4. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-602.
5. Chen A, Huang Z, Wan X, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012;35:474-81.
6. Kramer CK, Choi H, Zinman B, et al. Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 2013;305:E1398-407.
7. Kramer CK, Zinman B, Choi H, et al. Effect of short-term intensive insulin therapy on post-challenge hyperglucagonemia in early type 2 diabetes. J Clin Endocrinol Metab 2015;100:2987-95.
8. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012;14(Suppl 3):161-6.
9. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32.
10. Retnakaran R, Kramer CK, Choi H, et al. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-8.
11. Kramer CK, Zinman B, Choi H, et al. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. J Clin Endocrinol Metab 2015;100:3702-9.
12. Kramer CK, Choi H, Zinman B, et al. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care 2014;37:1116-23.
13. Retnakaran R, Qi Y, Opsteen C, et al. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010;12:909-15.
14. Retnakaran R, Yakubovich N, Qi Y, et al. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:65-71.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
17. Retnakaran R, Shen S, Hanley AJ, et al. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008;16:1901-7.
18. Retnakaran R, Qi Y, Goran MI, et al. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 2009;26:1198-203.
19. DeFronzo RA, Tripathy D, Schwenke DC, et al, ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-15.
20. Defronzo RA, Tripathy D, Schwenke DC, et al, ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920-6.
21. Halban PA, Polonsky KS, Bowden DW, et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751-8.
22. Liu J, Liu J, Fang D, et al. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients. Endocr J 2013;60:725-32.
23. Liu L, Ke W, Wan X, et al. Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission. Diabetes Res Clin Pract 2015;108:250-7.
24. Retnakaran R. Novel strategies for inducing glycemic remission during the honeymoon phase of type 2 diabetes. Can J Diabetes 2015;39(Suppl 5):S142-7.
25. Stein CM, Kramer CK, Zinman B, et al. Clinical predictors and time course of the improvement in beta-cell function with short-term intensive insulin therapy in patients with type 2 diabetes. Diabet Med 2015;32:645-52.
26. Karter AJ, Nundy S, Parker MM, et al. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. Diabetes Care 2014;37:3188-95.
27. Wang GF, Yan YX, Xu N, et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg 2015;25:199-208.
28. Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 2016;39:166-74.
29. Wang Z, York NW, Nichols CG, et al. Pancreatic beta-cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab 2014;19:872-82.